"The Once A Day Protease Inhibitor Regimens"
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00242216 |
Recruitment Status
:
Completed
First Posted
: October 19, 2005
Results First Posted
: October 17, 2013
Last Update Posted
: January 15, 2014
|
Sponsor:
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Roberto Arduino, The University of Texas Health Science Center, Houston
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type: | Interventional |
---|---|
Study Design: | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition: |
HIV Infections |
Interventions: |
Drug: ritonavir-boosted atazanavir Drug: ritonavir-boosted fosamprenavir |

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
---|
Patients enrolled at a county clinic |
Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
---|
No text entered. |
Reporting Groups
Description | |
---|---|
Atazanavir | Atazanavir/ritonavir (300mg/100mg) once daily |
Fosamprenavir | Fosamprenavir/ritonavir (1400mg/100mg) once daily |
Participant Flow: Overall Study
Atazanavir | Fosamprenavir | |
---|---|---|
STARTED | 39 | 37 |
COMPLETED | 21 | 15 |
NOT COMPLETED | 18 | 22 |
Lost to Follow-up | 12 | 17 |
Death | 4 | 2 |
Lack of Efficacy | 1 | 2 |
no medicaiton dispensed | 1 | 1 |


Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
---|
High porportion of subject did not complete the study. |